Finance

Lists
ABT:NYSE
Abbott Laboratories
US$107.29
-1.88%
(-2.06) 1D
ኖቬም 12, 2:15:45 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABT...
Open
US$110.32
High
US$110.78
Low
US$107.22
Mkt. cap
185.82 ቢ
Avg. vol.
9.62 ሚ
Volume
3.88 ሚ
Dividend
2.35%
Quarterly dividend
US$0.63
Ex-dividend date
15 ኦክቶ 2026
P/E ratio
39.79
52-wk high
US$132.02
52-wk low
US$81.97
EPS
US$2.70
Beta
0.54
Shares outstanding
1.73 ቢ
No. of employees
115 ሺ
Open
US$110.32
High
US$110.78
Low
US$107.22
Mkt. cap
185.82 ቢ
Avg. vol.
9.62 ሚ
Volume
3.88 ሚ
Dividend
2.35%
Quarterly dividend
US$0.63
Ex-dividend date
15 ኦክቶ 2026
P/E ratio
39.79
52-wk high
US$132.02
52-wk low
US$81.97
EPS
US$2.70
Beta
0.54
Shares outstanding
1.73 ቢ
No. of employees
115 ሺ
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories
CEORobert B. Ford
Employees115 ሺ
Founded1888
Headquartersሺካጎ, ኢሊኖይ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryMedical device
Websiteabbott.com
Analyst ratings
Based on 19 analysts giving stock ratings to ABT in the past 3 months
Strong buy
Buy
17
Hold
2
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for ABT in the last 3 months.
Highest
Current US$107.29
US$135.00 (+25.83%)
Average
US$122.56 (+14.23%)
Lowest
US$115.00 (+7.19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Travis Steed
Bank of America Securities
Buy
Maintained
US$125.00
+16.5%
11/09/2026
Adam Maeder
Piper Sandler
Buy
Maintained
US$118.00
+10%
11/02/2026
David Toung
Argus Research
Hold
Downgraded
-
-
10/26/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
US$120.00
+11.8%
10/23/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
US$120.00
+11.8%
10/22/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
US$115.00
+7.2%
10/22/2026
Josh Jennings
TD Cowen
Buy
Reiterated
US$118.00
+10%
10/22/2026
Kendall Au
RBC Capital
Buy
Maintained
US$125.00
+16.5%
10/21/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
US$125.00
+16.5%
10/21/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
US$118.00
+10%
10/22/2026
David Rescott
Robert W. Baird
Buy
Maintained
US$123.00
+14.6%
10/22/2026
Marie Thibault
BTIG
Buy
Maintained
US$125.00
+16.5%
10/21/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
US$120.00
+11.8%
10/23/2026
Christopher Pasquale
Barclays
Buy
Maintained
US$120.00
+11.8%
10/22/2026
Joanne Wuensch
Citi
Buy
Reiterated
US$122.00
+13.7%
10/22/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
10/12/2026
Matt Miksic
Barclays
Buy
Maintained
US$120.00
+11.8%
10/07/2026
Himanshu Patel
J.P. Morgan
Buy
Initiated
US$120.00
+11.8%
10/07/2026
Ed Ridley-Day
Rothschild & Co Redburn
Buy
Upgraded
US$127.00
+18.4%
10/02/2026
Matthew Taylor
Jefferies
Buy
Reiterated
US$135.00
+25.8%
08/21/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
US$130.00
+21.2%
08/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
US$125.00
+16.5%
07/28/2026
Patrick Wood
UBS
Buy
Reiterated
US$125.00
+16.5%
07/28/2026
Unknown Analyst
Jefferies
Buy
Reiterated
US$135.00
+25.8%
07/17/2026
Jayson Bedford
Raymond James
Buy
Maintained
-
-
07/17/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
US$110.00
+2.5%
06/29/2026
David Roman
Goldman Sachs
Buy
Maintained
US$113.00
+5.3%
05/31/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
US$92.00
-14.3%
04/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
US$115.00
+7.2%
04/20/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
US$115.00
+7.2%
04/17/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
US$120.00
+11.8%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
US$121.00
+12.8%
04/09/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Last report
21 ኦክቶ 2026
Fiscal period
Q3 2026
US$1.42 / US$1.42
+0.03%beat
Revenue / Est. (USD)
13.01 ቢ / 12.99 ቢ
+0.18%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
11.46 ቢ
11.16 ቢ
12.59 ቢ
13.01 ቢ
Cost of goods sold
4.91 ቢ
4.89 ቢ
5.32 ቢ
5.63 ቢ
Cost of revenue
4.91 ቢ
4.89 ቢ
5.32 ቢ
5.63 ቢ
Research and development expenses
720.00 ሚ
767.00 ሚ
892.00 ሚ
920.00 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.93 ቢ
3.58 ቢ
3.87 ቢ
4.11 ቢ
Operating expense
4.07 ቢ
4.77 ቢ
5.42 ቢ
5.87 ቢ
Total operating expenses
8.98 ቢ
9.66 ቢ
10.74 ቢ
11.50 ቢ
Operating income
2.48 ቢ
1.50 ቢ
1.85 ቢ
1.52 ቢ
Other non operating income
-15.00 ሚ
-
-25.00 ሚ
5.00 ሚ
EBT including unusual items
2.36 ቢ
1.45 ቢ
1.52 ቢ
1.23 ቢ
EBT excluding unusual items
2.44 ቢ
1.45 ቢ
1.52 ቢ
1.23 ቢ
Income tax expense
582.00 ሚ
372.00 ሚ
596.00 ሚ
311.00 ሚ
Effective tax rate
24.68%
25.67%
39.11%
25.26%
Other operating expenses
-
-
-
-
Net income
1.78 ቢ
1.08 ቢ
928.00 ሚ
920.00 ሚ
Net profit margin
15.50%
9.65%
7.37%
7.07%
Earnings per share
1.50
1.15
1.31
1.42
Interest and investment income
78.00 ሚ
106.00 ሚ
52.00 ሚ
53.00 ሚ
Interest expense
-120.00 ሚ
-174.00 ሚ
-351.00 ሚ
-350.00 ሚ
Net interest expenses
-42.00 ሚ
-68.00 ሚ
-299.00 ሚ
-297.00 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
3.27 ቢ
2.31 ቢ
2.91 ቢ
2.77 ቢ
Gain or loss from assets sale
65.00 ሚ
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች